Biosimilar trastuzumab candidate shows ‘similarity’ to Herceptin

05:07 EDT 11 Aug 2017 | Generics and Biosimilars Initiative

Results of a phase III clinical study of Celltrion’s biosimilar trastuzumab candidate CT‑P6 demonstrated the ‘similarity’ of the efficacy and safety compared to the originator biological (Herceptin) in patients with HER2+ breast cancer [1].

Original Article: Biosimilar trastuzumab candidate shows ‘similarity’ to Herceptin


More From BioPortfolio on "Biosimilar trastuzumab candidate shows ‘similarity’ to Herceptin"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...